Adjuvant capecitabine plus bevacizumab versus capecitabine alone in patients with colorectal cancer (QUASAR 2): an open-label, randomised phase 3 trial

• Published in: The lancet oncology Vol. 17; no. 11; pp. 1543 - 1557
• Main Authors: Kerr, Rachel S, Dr, Love, Sharon, BSc, Segelov, Eva, FRACP, Johnstone, Elaine, PhD, Falcon, Beverly, PhD, Hewett, Peter, FRACS, Weaver, Andrew, MD, Church, David, MRCP, Scudder, Claire, MSc, Pearson, Sarah, BSc, Julier, Patrick, MSc, Pezzella, Francesco, Prof, Tomlinson, Ian, Prof, Domingo, Enric, PhD, Kerr, David J, FRCP
• Format: Journal Article
• Language: English
• Published: England Elsevier Ltd 01.11.2016; Elsevier Limited
• Subjects: Aged; Antimetabolites, Antineoplastic - adverse effects; Antimetabolites, Antineoplastic - therapeutic use; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Bevacizumab - administration & dosage; Bevacizumab - adverse effects; Biomarkers; Cancer therapies; Capecitabine - administration & dosage; Capecitabine - adverse effects; Capecitabine - therapeutic use; Chemotherapy; Colorectal cancer; Colorectal Neoplasms - drug therapy; Colorectal Neoplasms - mortality; Female; Hematology, Oncology and Palliative Medicine; Humans; Male; Middle Aged; Population; Surgery; Tumors

Summary Background Antiangiogenic agents have established efficacy in the treatment of metastatic colorectal cancer. We investigated whether bevacizumab could improve disease-free survival in the adjuvant setting after resection of the primary tumour. Methods For the open-label, randomised, controll...